Literature DB >> 15987924

The maze of treatments for hepatitis B.

Anna Suk-Fong Lok.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15987924     DOI： 10.1056/NEJMe058119

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

1.  Clinical update: hepatitis B.

Authors:  Tram T Tran
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-07

2.  Increased frequency of circulating Th17 cells in acute-on-chronic hepatitis B liver failure.

Authors:  Li-Yuan Wang; Qing-Hua Meng; Zhi-Qiang Zou; Yu-Chen Fan; Jie Han; Zhao-Xia Qi; Jian Ge; Ai-Ling Xu; Si-Kui Wang; Kai Wang
Journal:  Dig Dis Sci       Date:  2011-10-08       Impact factor: 3.199

3.  Tea polyphenols exerts anti-hepatitis B virus effects in a stably HBV-transfected cell line.

Authors:  Pian Ye; Shuling Zhang; Lei Zhao; Jihua Dong; Shenghua Jie; Ran Pang; Shuli Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28

4.  A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B.

Authors:  D Eldon Spackman; David L Veenstra
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 5.  Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.

Authors:  Steven-Huy B Han
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.

Authors:  Pham Thi Le Hoa; Nguyen Tien Huy; Le The Thu; Cao Ngoc Nga; Kazuhiko Nakao; Katsumi Eguchi; Nguyen Huu Chi; Bui Huu Hoang; Kenji Hirayama
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

7.  Interleukin-6 upregulates Th17 response via mTOR/STAT3 pathway in acute-on-chronic hepatitis B liver failure.

Authors:  Hee Yeon Kim; Joo Yeon Jhun; Mi-La Cho; Jong Young Choi; Jae Kyeong Byun; Eun-Kyung Kim; Seung Kew Yoon; Si Hyun Bae; Byung Ha Chung; Chul Woo Yang
Journal:  J Gastroenterol       Date:  2013-12-25       Impact factor: 7.527

8.  Chronic HBV carrier's acceptance of regular surveilling program in China.

Authors:  Qing Fang; You-Hua Hao; Lei Li; Zhen-Hua Zhang; Jun-Zhong Wang; Ming-Fa Chen; Jian Kang; Dong-Liang Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-04-17

9.  Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B.

Authors:  Edward G Bridges; Jules R Selden; Shouqi Luo
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

10.  Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation.

Authors:  Jessica P Hwang; Manal M Hassan
Journal:  BMC Cancer       Date:  2009-02-04       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.